SGLT2 just some .... Pet lovers share the same risk of developing the condition as their pooches... because they lead similar lifestyles
https://www.dailymail.co.uk/news/article-9041537/Pet-lovers-share-risk-developing-type-2-diabetes-canines.html
"Pet lovers share the same risk of developing type 2 diabetes as their canines, researchers have found."
Top Cardiology Trials of 2020 in Review / December 15, 2020
https://www.medscape.com/viewarticle/942580
"The annual tradition continues as did cardiology research despite a pandemic.
Trials on fish oils, statins, SGLT2 inhibitors, and antiplatelets are among
the selections of Drs Harrington and Gibson."
Eli Lilly and Company (LLY) CEO Dave Ricks on 2021 Guidance/Update Results - Earnings Call Transcript / Dec. 15, 2020
https://seekingalpha.com/article/4394929-eli-lilly-and-company-lly-ceo-dave-ricks-on-2021-guidance-update-results-earnings-call
"New patient starts in the SGLT2 class have largely returned to pre-COVID baselines, which we expect will lead to further
acceleration of the SGLT2 class in 2021."
Lexicon Buoyed By Renewed Enthusiasm For The Pipeline / Dec. 15, 202
https://seekingalpha.com/article/4394906-lexicon-buoyed-renewed-enthusiasm-for-pipeline
"Multiple SGLT-2 inhibitors have shown cardiac outcome benefits, and I remain unconvinced
that sotagliflozin can separate itself from the pack of established, commercialized SGLT-2's."
Big pharma catalysts to ring in the new year / December 15, 2020
https://www.evaluate.com/vantage/articles/events/company-events/big-pharma-catalysts-ring-new-year
"Astrazeneca’s own SGLT2 Farxiga is already on the market for reduced ejection fraction but its equivalent
trial in preserved ejection patients called Deliver is still recruiting and will likely read out towards
the end of 2021."